At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 95 enrolled
Drug / intervention
Cytarabine +3 moredrug
Likely dose
Cytarabine 3 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study on Gemtuzumab Ozogamicin in Combination With All-trans-Retinoic Acid, High-dose Cytarabine and Mitoxantrone in Patients With Primary Refractory Acute Myeloid Leukemia
In Brief
A Phase 2 clinical trial evaluating Cytarabine, Mitoxantrone, and 2 other interventions for Leukemia, Myeloid, Acute. Completed, enrolled 95 participants across 27 sites in 2 countries.
Detailed Summary
GO-A-HAM: Gemtuzumab Ozogamicin 3g/m² day 1 Cytarabine 3g/m² bid days 1-3 Mitoxantrone 12mg/m² days 2,3 All-trans Retinoic acid 45mg/m² days 4-6 and 15 mg/m² days 7-28
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Myeloid, Acute
CountriesAustria, Germany
Collaborators--
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2004
First PostedSep 2005
Primary CompletionJul 2007
Study CompletionJun 2009
TodayJul 2026
First PostedSep 2, 2005
Enrollment StartJun 1, 2004
Primary CompletionJul 1, 2007
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 20.8 years ago
Interventions
Cytarabinedrug
3 g/m2 bid. i.v day 1-3
Mitoxantronedrug
12 mg/m2 i.v. day 2 and 3
Gemtuzumab Ozogamicindrug
3mg/m² i.v. day 1
All-trans-Retinoid Aciddrug
45 mg/m2 p.o. day 4-6 15 mg/m2 p.o. day 7-28